Puma Biotechnology, Inc. (PBYI) is a Healthcare stock trading at $9.24 (as of 2026-08-21), with a market capitalization of $476.97M and a trailing P/E of 17.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Puma Biotechnology develops and commercializes oral biopharmaceutical treatments for cancer (including PB272 neratinib across HER2-positive breast cancer and HER2 mutation-positive solid tumors), and it makes money primarily from Net Product Revenue and Royalty Revenue tied to its commercialization and licensing arrangements.
Earnings are driven by (1) Net Product Revenue from Near-Links sales, (2) Royalty Revenue under licensing (including a Pfizer license), and (3) quarterly timing effects from changes in inventory held by specialty pharmacies and specialty distributors (inventory drawdown impact to product revenue).
| NearLinks | $0.0B |
| Royalties | $0.0B |
| Other | $0.0B |
Business quality (Weak): The latest quarter shows high gross margin (76.7%) but a negative operating margin (-8.5%), implying profitability depends on scaling product and royalty contributions while controlling operating costs and managing inventory-related timing effects.
Valuation: At 17× earnings, PBYI trades in line with the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $9.24 |
| Market Cap | $476.97M |
| P/E Ratio | 17.9 |
| EV / EBITDA | 10.1 |
| Price / Book | 3.44 |
| Price / Sales | 2.06 |
| FCF Yield | 8.6% |
| DCF Value (model) | $14.39 |
| DCF Upside vs Price | 55.7% |
| Revenue (TTM) | $228.37M |
| Net Margin | 13.6% |
| Revenue Growth (YoY) | 7.8% |
| EPS Growth (YoY) | 33.3% |
| FCF Growth (YoY) | -88.5% |
| Altman Z-Score | -2.95 (distress) |
| Piotroski F-Score | 7/9 (strong) |
| Stock P/E | 17.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -17.9% |
| vs Industry | 3.9% |
| Top Institutional Holder | ACORN CAPITAL ADVISORS, LLC ($26.40M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Alan H. Auerbach |
| Employees | 172 |
| Country | US |
| IPO Date | 2012-04-24 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.